Latest news with #MarianodeSocarraz
Yahoo
30-05-2025
- Health
- Yahoo
AIxMed and CorePlus Partner to Demonstrate a Digital Urine Cytology Workflow Solution
AIxMed and CorePlus team up to bring AI-driven quality control to improve bladder cancer diagnostics. SANTA CLARA, Calif., May 30, 2025 /PRNewswire/ -- AIxMed, innovators and providers of an AI-powered computational platform for cytology applications, and CorePlus have entered a Memorandum of Understanding to evaluate a Quality Control workflow solution for urine cytology. The partnership aims to demonstrate the integration of artificial intelligence into the urine cytology workflow, enhancing diagnostic consistency, efficiency, and scalability. AIxMed's experience in AI-based cytology software and analysis, combined with CorePlus' experience in integrating digital and AI solutions into their day-to-day pathology workflow will come together to provide an end-to-end solution for research-use only cytology analysis. "We are thrilled to collaborate with CorePlus in demonstrating how AIxURO can seamlessly integrate into their digital pathology workflow. This effort builds on the success of our previous studies and marks an important milestone toward modernizing cytology quality control (QC) through digital and AI tools," said Samuel Chen, CEO of AIxMed. "AIxURO offers significant time savings with consistent results. Integrating our scanner with real-time AI-based QC checks significantly improves efficiency and diagnostic accuracy. Precision cytology is no longer a vision—it's reality," said Mariano de Socarraz, Founder, and CEO of CorePlus. The scarcity of cytologists and the manual process involved in cell characterization necessitate the development of advanced tools to enhance workflow and offer both quantitative and qualitative insights. AI-driven computational tools have the potential to provide these valuable insights and enable the processing of a greater number of slides with the existing workforce. To learn more about these solutions or to request a demonstration, please visit About AIxMedFounded in 2018, AIxMed is creating a roadmap to transforming cancer diagnosis and monitoring through our smart computational cytology platform. This solution simplifies clinical workflows and richly strengthens the quality of healthcare by aiding critical decision support during clinical diagnosis and monitoring. To learn more visit About CorePlusCorePlus is a state-of-the-art precision pathology organization based in Puerto Rico, committed to diagnostic excellence through innovation and technology. With a patient-centered approach and quality-driven processes, CorePlus is at the forefront of adopting artificial intelligence algorithms as decision support tools for our pathologists offering unprecedented accuracy and efficiency. To learn more visit View original content to download multimedia: SOURCE AIxMed, Inc.
Malaysian Reserve
28-05-2025
- Health
- Malaysian Reserve
CorePlus Puerto Rico Publishes Groundbreaking Study on Implementing 100% Quality Control in Cervical Cytology Using Whole Slide Imaging and Artificial Intelligence
CAROLINA, Puerto Rico, May 27, 2025 /PRNewswire/ — CorePlus, a leading precision pathology organization in Puerto Rico, has announced the publication of a landmark study validating the use of artificial intelligence (AI) and whole slide imaging (WSI) as a 100% quality control (QC) tool in cervical cytology workflows. The study was published in the prestigious peer-reviewed journal Cancer Cytopathology, underscoring its scientific rigor and clinical relevance. Revolutionizing Cytology with AI and Digital Pathology As digital pathology continues to advance into the field of cytopathology, laboratories are exploring alternatives to traditional manual microscopy screening. CorePlus evaluated the performance of the Techcyte SureView™ system—specifically designed for digital cytopathology—on 1,442 digitized slides from ThinPrep® and SurePath™ cervical cytology samples. The slides were scanned using the 3DHISTECH P1000 DX scanner under both dry and water immersion scanning profiles. A board-certified cytopathologist reviewed AI-identified objects of interest and compared them to results obtained through traditional light microscopy. Outstanding Results and Operational Efficiency The study demonstrated that the SureView™ system using the water immersion profile significantly outperformed both dry scanning and manual microscopy in detecting squamous and glandular abnormalities. Key performance metrics included: 97% accuracy 82% sensitivity 99% specificity 98% negative predictive value 86% positive predictive value In addition to its high diagnostic performance, the AI-assisted system considerably reduced review times and improved overall workflow efficiency. A New Standard for Quality Control in Cervical Cytology Following successful validation, CorePlus has fully integrated the Techcyte SureView™ system as a 100% QC tool in its laboratory operations. This marks a major step forward in adopting digital and AI technologies to enhance diagnostic accuracy, laboratory efficiency, and patient care. 'We have been able to achieve an unprecedented level of consistency and confidence in cervical cytology screening, every PAP Counts!' Mariano de Socarraz, Founder and Chief Executive Officer at CorePlus. 'Our team is proud to contribute to the advancement of digital pathology and demonstrate its real-world clinical impact.' For access to the complete published study please visit: Implementing 100% quality control in a cervical cytology workflow using whole slide images and artificial intelligence provided by the Techcyte SureView™ System – Rivera Rolon – 2025 – Cancer Cytopathology – Wiley Online Library About CorePlus CorePlus is a state-of-the-art precision pathology organization based in Puerto Rico, committed to diagnostic excellence through innovation and technology. With a patient-centered approach and quality-driven processes, CorePlus is at the forefront of adopting artificial intelligence algorithms as decision support tools for our pathologists offering unprecedented accuracy and efficiency. About Cancer Cytopathology Cancer Cytopathology is a peer-reviewed medical journal published by the American Cancer Society. Internationally recognized, it focuses on the science and practice of cancer cytopathology. The journal publishes innovative research, clinical studies, and expert reviews aimed at improving diagnostic accuracy and outcomes in cancer management. The publication of the CorePlus study in Cancer Cytopathology highlights its significant contribution to the advancement of digital cytopathology in cancer diagnostics and quality control. About Techcyte Founded in 2013, Techcyte is transforming the practice of pathology with a unified pathology platform that digitizes lab workflows and offers AI tools that improve the efficiency and accuracy of diagnostic testing. Our mission is to positively impact the health of humans, animals, and the environment through the use of artificial intelligence. We do that by partnering with best-in-class labs, whole slide scanner manufacturers, AI vendors, diagnostic companies, hardware manufacturers, and solution providers. Together, we aim to deliver a unified clinical and anatomic pathology platform to labs and clinics around the world. Visit for more information. About Epredia Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523) offers a unique array of end-to-end instruments for pathology workflows including tissue processors, microtomes, embedding stations, and a range of 3DHistech developed whole slide scanners from the single slide Pannoramic Desk II to the Pannoramic 1000 scanner. These scanners offer a single slide to 1000 slide capacity and a throughput of up to 85 slides per hour, including overnight scanning. Visit for more information.
Yahoo
27-05-2025
- Health
- Yahoo
CorePlus Puerto Rico Publishes Groundbreaking Study on Implementing 100% Quality Control in Cervical Cytology Using Whole Slide Imaging and Artificial Intelligence
CAROLINA, Puerto Rico, May 27, 2025 /PRNewswire/ -- CorePlus, a leading precision pathology organization in Puerto Rico, has announced the publication of a landmark study validating the use of artificial intelligence (AI) and whole slide imaging (WSI) as a 100% quality control (QC) tool in cervical cytology workflows. The study was published in the prestigious peer-reviewed journal Cancer Cytopathology, underscoring its scientific rigor and clinical relevance. Revolutionizing Cytology with AI and Digital Pathology As digital pathology continues to advance into the field of cytopathology, laboratories are exploring alternatives to traditional manual microscopy screening. CorePlus evaluated the performance of the Techcyte SureView™ system—specifically designed for digital cytopathology—on 1,442 digitized slides from ThinPrep® and SurePath™ cervical cytology samples. The slides were scanned using the 3DHISTECH P1000 DX scanner under both dry and water immersion scanning profiles. A board-certified cytopathologist reviewed AI-identified objects of interest and compared them to results obtained through traditional light microscopy. Outstanding Results and Operational Efficiency The study demonstrated that the SureView™ system using the water immersion profile significantly outperformed both dry scanning and manual microscopy in detecting squamous and glandular abnormalities. Key performance metrics included: 97% accuracy 82% sensitivity 99% specificity 98% negative predictive value 86% positive predictive value In addition to its high diagnostic performance, the AI-assisted system considerably reduced review times and improved overall workflow efficiency. A New Standard for Quality Control in Cervical Cytology Following successful validation, CorePlus has fully integrated the Techcyte SureView™ system as a 100% QC tool in its laboratory operations. This marks a major step forward in adopting digital and AI technologies to enhance diagnostic accuracy, laboratory efficiency, and patient care. "We have been able to achieve an unprecedented level of consistency and confidence in cervical cytology screening, every PAP Counts!" Mariano de Socarraz, Founder and Chief Executive Officer at CorePlus. "Our team is proud to contribute to the advancement of digital pathology and demonstrate its real-world clinical impact." For access to the complete published study please visit: Implementing 100% quality control in a cervical cytology workflow using whole slide images and artificial intelligence provided by the Techcyte SureView™ System - Rivera Rolon - 2025 - Cancer Cytopathology - Wiley Online Library About CorePlus CorePlus is a state-of-the-art precision pathology organization based in Puerto Rico, committed to diagnostic excellence through innovation and technology. With a patient-centered approach and quality-driven processes, CorePlus is at the forefront of adopting artificial intelligence algorithms as decision support tools for our pathologists offering unprecedented accuracy and efficiency. About Cancer Cytopathology Cancer Cytopathology is a peer-reviewed medical journal published by the American Cancer Society. Internationally recognized, it focuses on the science and practice of cancer cytopathology. The journal publishes innovative research, clinical studies, and expert reviews aimed at improving diagnostic accuracy and outcomes in cancer management. The publication of the CorePlus study in Cancer Cytopathology highlights its significant contribution to the advancement of digital cytopathology in cancer diagnostics and quality control. About Techcyte Founded in 2013, Techcyte is transforming the practice of pathology with a unified pathology platform that digitizes lab workflows and offers AI tools that improve the efficiency and accuracy of diagnostic testing. Our mission is to positively impact the health of humans, animals, and the environment through the use of artificial intelligence. We do that by partnering with best-in-class labs, whole slide scanner manufacturers, AI vendors, diagnostic companies, hardware manufacturers, and solution providers. Together, we aim to deliver a unified clinical and anatomic pathology platform to labs and clinics around the world. Visit for more information. About Epredia Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523) offers a unique array of end-to-end instruments for pathology workflows including tissue processors, microtomes, embedding stations, and a range of 3DHistech developed whole slide scanners from the single slide Pannoramic Desk II to the Pannoramic 1000 scanner. These scanners offer a single slide to 1000 slide capacity and a throughput of up to 85 slides per hour, including overnight scanning. Visit for more information. View original content to download multimedia: SOURCE CorePlus Servicios Clinicos y Patologicos, LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
